Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Bookmark and Share
Published: 5 Jun 2022
Views: 21
Rating:
Save
Dr Julie Gralow- Chief Medical Officer, ASCO

Dr Julie Gralow comments on the phase 3 DETERMINATION trial using Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM).

The primary outcome was that Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance prolongs disease control and improves survival for newly diagnosed multiple myeloma patients.

Dr Gralow concludes the by discussing the significance of the study findings.

Watch Dr Richardson's interview on the study here

Watch Dr Richardson's press conference on the study here

Read the news article here